Per page
Case | Severity | Reported | Quarter | Manufacturer | Country | Suspect drugs | Reactions | Outcomes |
|---|---|---|---|---|---|---|---|---|
2487259212v12 | Serious | May 31 | '25Q2 | United Therapeutics | US | OrenitramAmoxicillin | Medically important | |
2368052816v16 | Serious | May 31 | '25Q2 | Celltrion | CA | Inflectra | Off Label Use | Medically importantHospitalization |
2345545512v12 | Serious | May 31 | '25Q2 | Takeda | AU | Vedolizumab | Medically importantHospitalization | |
2214412016v16 | Serious | May 31 | '25Q2 | Celltrion | CA | Inflectra | HospitalizationMedically important | |
2187005123v23 | Serious | May 31 | '25Q2 | Takeda | US | Human Immunoglobulin GModerna Covid-19 Vaccine | Tooth Abscess | HospitalizationMedically important |
2018016811v11 | Serious | May 31 | '25Q2 | Takeda | CA | MethotrexateVedolizumab | Medically important | |
1837021975v75 | Serious | May 31 | '25Q2 | Celltrion | CA | Inflectra | Drug Level Above Therapeutic | HospitalizationMedically important |
1801173519v19 | Serious | May 31 | '25Q2 | Aurobindo | DE | RamiprilSpinraza | Medically important | |
1735636814v14 | Serious | May 31 | '25Q2 | Takeda | US | Human Immunoglobulin G | Multiple Allergies | HospitalizationMedically important |
1733334216v16 | Serious | May 31 | '25Q2 | Takeda | CA | Pantoprazole SodiumVedolizumab | Volvulus Of Small Bowel | HospitalizationMedically important |
1706903938v38 | Serious | May 31 | '25Q2 | Celltrion | CA | Inflectra | Blood Pressure Fluctuation | Medically important |
1600414047v47 | Serious | May 31 | '25Q2 | Celltrion | CA | Inflectra | Blood Pressure Increased | HospitalizationMedically important |
253862281v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Herbals\Mitragynine7-Hydroxymitragynine | Feeling Abnormal | Medically importantIntervention requiredDisability |
253861651v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Zepbound | Intervention required | |
253861561v1 | None | May 31 | '25Q2 | Fda-Ctu | US | Zyrtec | None | |
253861431v1 | None | May 31 | '25Q2 | Fda-Ctu | US | Zyrtec | None | |
253861291v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | ZyrtecCetirizine Hydrochloride | Autoimmune Thyroiditis | Medically important |
253860961v1 | Serious | May 31 | '25Q2 | Fda-Ctu | VE | Zoloft | Erectile Dysfunction | Medically important |
253860771v1 | Serious | May 31 | '25Q2 | Fda-Ctu | GB | Venlafaxine | Impaired Work Ability | Life-threateningIntervention required |
253860751v1 | None | May 31 | '25Q2 | Fda-Ctu | US | Zavzpret | Neck Pain | None |
253860741v1 | None | May 31 | '25Q2 | Fda-Ctu | US | Xyzal | None | |
253860681v1 | Serious | May 31 | '25Q2 | Fda-Ctu | CA | Tirzepatide | Abdominal Pain Upper | Disability |
253860421v1 | None | May 31 | '25Q2 | Fda-Ctu | US | Tirzepatide | Gastrooesophageal Reflux Disease | None |
253860201v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Sertraline | Withdrawal Syndrome | Intervention required |
253860151v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Sertraline | Visual Impairment | HospitalizationIntervention requiredDisability |
253860111v1 | None | May 31 | '25Q2 | Fda-Ctu | US | Rinvoq | None | |
253860091v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | RosuvastatinPaxlovid | Blood Pressure Increased | Intervention requiredMedically important |
253859441v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Reclast | Medically important | |
253859421v1 | Serious | May 31 | '25Q2 | Fda-Ctu | GB | Prozac | Hospitalization | |
253859371v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Mounjaro | Medically important | |
253859351v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Paxil | General Physical Health Deterioration | Disability |
253859331v1 | Death | May 31 | '25Q2 | Fda-Ctu | MY | DonepezilMemantine Hydrochloride | Klebsiella Test Positive | Death |
253859291v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Metoclopramide | General Physical Health Deterioration | Intervention requiredDisabilityLife-threatening |
253859001v1 | None | May 31 | '25Q2 | Fda-Ctu | US | Cetirizine | None | |
253858901v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Fluorouracil | Medically important | |
253858571v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | DiazepamHaldol | Depersonalisation/Derealisation Disorder | Intervention requiredHospitalization |
253858531v1 | Serious | May 31 | '25Q2 | Fda-Ctu | CA | Effexor | Weight Decreased | DisabilityHospitalization |
253858521v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Duloxetine | Life-threateningDisability | |
253858051v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Clonazepam | Nerve Injury | HospitalizationIntervention requiredDisability |
253857951v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Claravis | Therapy Interrupted | Medically important |
253857801v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Citalopram | Blunted Affect | Medically important |
253857771v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Vitamin CCetirizine | Malassezia Infection | Intervention required |
253857701v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Ceftriaxone | Hospitalization | |
253857611v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Brimonidine TartrateLatanoprost | Burning Sensation | Disability |
253857511v1 | None | May 31 | '25Q2 | Fda-Ctu | US | Amoxicillin\Clavulanate Potassium | None | |
253856601v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | Venlafaxine Hydrochloride | Medically importantIntervention required | |
253856581v1 | Serious | May 31 | '25Q2 | Fda-Ctu | DE | Celexa | DisabilityMedically importantHospitalization | |
253856041v1 | Serious | May 31 | '25Q2 | Fda-Ctu | US | FluoxetineSertraline | Intervention requiredLife-threateningDisability | |
253855901v1 | Death | May 31 | '25Q2 | Fda-Ctu | US | Kisqali | Death | |
253855811v1 | Death | May 31 | '25Q2 | Fda-Ctu | US | Prolia | Renal Failure | Death |
Showing 1-50 of 1,330,158